Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News INmune Bio Inc INMB

Healthcare Biotechnology
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform. The DN-TNF product platform utilizes dominant-negative technology to... see more

Recent & Breaking News (NDAQ:INMB)

INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium

GlobeNewswire November 29, 2023

INmune Bio Receives EMA's Authorization in France and Spain for Phase II Clinical Trial of XPro(TM) for Early Alzheimer's Disease

GlobeNewswire November 27, 2023

INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer's Disease in Europe

GlobeNewswire November 15, 2023

INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update

GlobeNewswire November 1, 2023

INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune(TM) Therapeutic Composition given Favorable Patentability Opinion by International Search Authority

GlobeNewswire October 31, 2023

INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα

GlobeNewswire October 30, 2023

INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro(TM) to Treat Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference

GlobeNewswire October 17, 2023

INmune Bio Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, November 1

GlobeNewswire October 16, 2023

INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 7, 2023

INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer's Disease

GlobeNewswire September 5, 2023

INmune Bio Inc. Announces Second Quarter 2023 Results and Provides Business Update

GlobeNewswire August 7, 2023

INmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference

GlobeNewswire August 1, 2023

INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7

GlobeNewswire July 31, 2023

INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference.

GlobeNewswire July 12, 2023

INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer's Disease

GlobeNewswire July 11, 2023

INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro(TM) Promotes Remyelination by Affecting Astroglial and Microglial Biology

GlobeNewswire July 10, 2023

INmune Bio Inc.'s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy

GlobeNewswire May 24, 2023

INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune(TM), a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer

GlobeNewswire May 8, 2023

INmune Bio Inc. Announces First Quarter 2023 Results and Provides Business Update

GlobeNewswire May 3, 2023

INmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3

GlobeNewswire April 24, 2023